John Cappleman, MD
Geriatric Medicine · Winter Garden, FLNPI 1790783389
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,100 of the $10,351 with a category attached, or 87.9%. It is spread thinly across 41 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,725 and has fallen 57.9% since, to $1,147 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$1K
- Pfizer$1K
- Lilly USA, LLC$850
- AstraZeneca$810
- AbbVie$571
- plus $4K from 35 others
What the payments were for
- Consulting fees$1,20012%
- Food & beverage$9,10088%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- RYBELSUS$207
- Ozempic$120
How this compares
$10,351 in reported general payments places this provider in the 95th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $155,467 |
| XareltoRivaroxaban | 76 | $73,590 |
| JardianceEmpagliflozin | 40 | $59,872 |
| OzempicSemaglutide | 43 | $53,302 |
| FarxigaDapagliflozin Propanediol | 24 | $31,754 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $31,140 |
| TrulicityDulaglutide | 33 | $30,687 |
| Bydureon BciseExenatide Microspheres | 13 | $21,724 |
| JanuviaSitagliptin Phosphate | 17 | $18,997 |
| MounjaroTirzepatide | 11 | $17,218 |
| EntrestoSacubitril/Valsartan | 16 | $17,134 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,832 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $9,796 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $9,373 |
| Sumatriptan Succinate | 33 | $9,327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,196 | $155,467136 claims |
| Johnson & JohnsonXarelto | $392 | $73,59076 claims |
| Boehringer IngelheimJardiance | $516 | $59,87240 claims |
| Novo NordiskOzempic | $1,400 | $53,30243 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $850 | $47,90544 claims |
| AstraZenecaFarxiga, Symbicort | $810 | $41,55051 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $395 | $39,74646 claims |
| MerckJanuvia | $108 | $18,99717 claims |
| NovartisEntresto | $204 | $17,13416 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $5,715546 claims |
| AbbVieSynthroid | $571 | $4,02346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Winter Garden
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.